Figure 1: Enrolment rate by trial phase in China. Credit: GlobalData.
Go deeper with GlobalData
On average, enrolment rates for clinical trials in China, which include both single-country and multinational trials, decrease as products move through the pipeline (Figure 1).
GlobalData looked at trials between January 2001 to April 2018 and found that Phase I trials have the highest enrolment rates, enrolling 15.5 subjects/site/month, and have the second largest number of trials, as shown by the bubble size in the figure below.
Phase III trials make up 54.8% of the total trials that were analysed, and have a low enrolment rate of 4.4 subjects/site/month. These later-stage trials often have such slow enrolment rates because they require the largest number of patients per trial.
For more insight and data, visit the GlobalData Report Store – Pharmaceutical Technology is part of GlobalData Plc.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
